The breakthrough for immunotherapy in oncology started with the approval of the anti-CTLA-4 monoclonal antibody ipilimumab for second-line treatment of advanced melanoma in 2011, and the following extension to first-line therapy in 2013. This evidence concerns the gene CTLA4 and melanoma.